tiprankstipranks
Trending News
More News >

Radiopharm Theranostics Expands Market Presence with New ASX Quotation

Story Highlights
Radiopharm Theranostics Expands Market Presence with New ASX Quotation

Don’t Miss TipRanks’ Half-Year Sale

Radiopharm Theranostics Limited ( (AU:RAD) ) has issued an announcement.

Radiopharm Theranostics Limited has announced the quotation of 30,969,360 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective June 11, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility and market presence, potentially impacting its operational capabilities and stakeholder interests positively.

The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is primarily involved in creating innovative solutions for cancer treatment and diagnosis, leveraging advanced technologies in the field of nuclear medicine.

Average Trading Volume: 4,325,527

Technical Sentiment Signal: Sell

Current Market Cap: A$56.02M

Find detailed analytics on RAD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1